Celldex Therapeutics’ (CLDX) “Buy” Rating Reaffirmed at HC Wainwright

Celldex Therapeutics (NASDAQ:CLDX)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a report issued on Monday,Benzinga reports. They presently have a $42.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s target price suggests a potential upside of 34.31% from the stock’s previous close.

A number of other research analysts have also recently issued reports on the company. Wells Fargo & Company lifted their price objective on Celldex Therapeutics from $38.00 to $54.00 and gave the company an “overweight” rating in a research note on Wednesday, May 13th. The Goldman Sachs Group increased their target price on Celldex Therapeutics from $30.00 to $34.00 and gave the stock a “neutral” rating in a research note on Monday, March 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Celldex Therapeutics in a report on Monday, April 20th. Barclays lifted their price target on Celldex Therapeutics from $45.00 to $48.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. Finally, Wall Street Zen upgraded shares of Celldex Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 9th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $49.30.

Celldex Therapeutics Stock Performance

Shares of CLDX opened at $31.27 on Monday. The stock has a market cap of $2.45 billion, a PE ratio of -7.34 and a beta of 0.95. Celldex Therapeutics has a fifty-two week low of $19.52 and a fifty-two week high of $35.79. The firm’s 50-day simple moving average is $31.88 and its two-hundred day simple moving average is $28.84.

Celldex Therapeutics (NASDAQ:CLDX) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.15) by ($0.03). The firm had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.80 million. Equities research analysts predict that Celldex Therapeutics will post -4.36 EPS for the current year.

Institutional Trading of Celldex Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Aster Capital Management DIFC Ltd purchased a new position in shares of Celldex Therapeutics in the third quarter worth $26,000. Wilmington Savings Fund Society FSB purchased a new stake in shares of Celldex Therapeutics during the third quarter valued at $42,000. Russell Investments Group Ltd. increased its holdings in Celldex Therapeutics by 27.6% in the 2nd quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 501 shares in the last quarter. Quantbot Technologies LP bought a new stake in Celldex Therapeutics in the 3rd quarter worth about $63,000. Finally, Kestra Advisory Services LLC purchased a new position in Celldex Therapeutics in the 4th quarter worth about $98,000.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.